Description

Cerebrovascular disease is one of the three principal diseases that can cause people to death. Acute cerebral infarction which occupies 70% of cerebrovascular disease has a disability rate of 50%-70% and a recurrence rate of 40%. And one thing to be noted is that the more relapses people have, the higher the mortality and disability.

View Full Report at: http://www.marketresearchreports.biz/analysis/289121

Acute cerebral infarction, one of the serious threats to old people’s health, features sudden onset, complex pathogenesis and “three high and one low”: high morbidity, high mortality, high fatality and low cure rate.

Edaravone injection, a life-saving drug for the treatment of acute cerebral infarction, is the only free radical scavenger in the world with a clear mechanism and target of acute cerebral infarction. Ever since its debut in Japan in 2002, its sales in the first 13 months has surpassed JPY 40 billion.

Simcere is China’s first and world’s second manufacturer of edaravone injection. Its new product “Bi Cun” is priced at 1/33 of the price of similar products in Japan. In 2007, “Bi Cun” spread over China with a market share of 74.62%. According to CRI’s statistics, edaravone develops fast after entering China, annual sales value rising from less than CNY 50 million in 2005 to CNY 629 million in 2014 and CAGR reaching up to 34.3% during the period of 2005-2015. Currently, local manufacturers of edaravone are as follows: Simcere, Jilin Boda Pharmaceutical Co., Ltd, Jilin Province Huinan Changlong Biopharmacy Co., Ltd and Kunming Jida Pharmaceutical Co., Ltd, among which Simcere has the largest market share of 39% with sales value reaching up to CNY 246 million in 2014.


Download Detail Report With Complete TOC at: http://www.marketresearchreports.biz/sample/sample/289121

With the ageing population, the incidence of acute cerebral infarction in China will keep increasing, thus promoting the growth of edaravone market.


Readers can get at least the following information from this report:

market size of edaravone in China
market share of manufacturers of edaravone in China
price of edaravone in Chinese market
major manufacturers of edaravone in Chinese market
market outlook of edaravone in China

The author suggests the following groups of people purchase this report:

manufacturers of cerebrovascular drugs
investors/ research institutions interested in Chinese medicine market
any interest in the Chinese medicine market, please contact CRI for customized survey service

Table of Content

1 Related Concepts of Edaravone
1.1 Indication
1.2 Sales Status in Global Market

2 Market Profile of Edaravone in China
2.1 Patent and Approval Status of Edaravone in China
2.2 Major Manufacturers
2.3 Market Size

3 Survey on Sales Status of Edaravone in China, 2010-2014
3.1 Sales Value
3.1.1 Overall Sales Value
3.1.2 Sales Value by Regions
3.2 Sales Volume
3.2.1 Overall Sales Volume
3.2.2 Sales Volume by Regions


Browse all latest Articles of Market Research Reports
at:http://www.marketresearchreports.biz/articles


About us

MarketResearchReports.biz is the most comprehensive collection of market research reports.
MarketResearchReports.Biz services are specially designed to save time and money for our clients.
We are a one stop solution for all your research needs, our main offerings are syndicated research
reports, custom research, subscription access and consulting services. We serve all sizes and types
of companies spanning across various industries.

Browse Our Press Releases by Prnewswire:
http://www.prnewswire.com/news/marketresearchreports.biz

Browse More PressRelease:
http://www.prweb.com/search.aspx?search-releases=marketresearchreports.biz

Contact
Mr. Nachiket
90 Sate Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA: Canada Toll Free: 866-997-4948
Website: http://www.marketresearchreports.biz/
E: [email protected]